FDA Approves Less Painful Formula of Humira Biosimilar for Autoimmune Disorders

Hadlima, developed by South Korea-based biotech firm Samsung Bioepis and to be commercialized by global healthcare company Organon, became the latest medication to gain the approval of the FDA for the treatment of several disorders, including arthritis, ulcerative colitis, and plaque psoriasis.